anabolic treatment osteoporosis

In the field of bone health, we have historically focused on “preservation.” For decades, the standard of care has been antiresorptive medications—drugs like bisphosphonates that slow down the rate at which the body breaks down bone. While effective for many, these drugs are essentially a defensive strategy. For patients with severe osteoporosis, characterized by a T-score of -2.5 or lower and a history of fragility fractures, defense is not enough.

We are now entering the era of Regenerative Bone Medicine. The introduction of anabolic agents has shifted the goal from merely stopping bone loss to actively rebuilding the skeletal architecture. By opening what clinicians call the “Anabolic Window,” these therapies allow us to regrow lost bone, significantly reducing future fracture risk in the highest-risk populations.